

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of Moshe Flashner-Barak

Group Art Unit:

1615

Application No.:

09/829,621

Examiner:

A. Pulliam

Filed:

April 10, 2001

Docket No.:

1662/52202

For:

METHOD OF TREATING CANCER BY ADMINISTRATION OF

FORMULATIONS CONTAINING APOPTOSIS-INDUCING

CHEMOTHERAPEUTIC AGENTS

INFORMATION DISCLOSURE STATEMENT

Director of the U.S. Patent and Trademark Office Washington, D.C. 20231

Sir:

Pursuant to 37 CFR § 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

03/13/2003 MAHMED1 00000022 110600 09829621

01 FC:1806

180.00 CH

Serial No. 09/829,621 Docket #: 1662/52202

This Information Disclosure Statement is being filed before the mailing date of a Final Rejection or Notice of Allowance. Please debit Deposit Account No. 11-0600 in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p) to ensure consideration of the disclosed information. A duplicate copy of the Fee Transmittal is attached.

Respectfully submitted,

KENYON & KENYON

Date: 3/10/03

W. David Wallace

Registration No. 42,210

KENYON & KENYON 1500 K Street, N.W., Suite 700 Washington, D.C. 20005

Telephone: 202-220-4200 Facsimile: 202-220-4201